Centessa Pharmaceuticals (CNTA) Times Interest Earned (2022 - 2026)
Centessa Pharmaceuticals (CNTA) reported Times Interest Earned of -$29.21 for Q1 2026, down 173.05% year-over-year from $39.98 in Q1 2025, and down 19.79% on a QoQ basis from -$24.38 in Q4 2025.
Centessa Pharmaceuticals (CNTA) has 5 years of Times Interest Earned data on file, last reported at -$29.21 in Q1 2026.
- Quarterly Times Interest Earned fell 173.05% year-over-year to -$29.21 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$22.69 (down 20.99% YoY) and the FY2025 annual result came in at -$18.12, up 9.04% from the prior year.
- Times Interest Earned eased to -$29.21 in Q1 2026 per CNTA's latest filing, from -$24.38 in the prior quarter.
- Across five years, Times Interest Earned topped out at -$10.7 in Q1 2025 and bottomed at -$41.39 in Q2 2022.
- The 5-year median for Times Interest Earned is -$18.95 (2025), against an average of -$21.92.
- The widest annual swing landed in 2023, when Times Interest Earned jumped 53.63%; it then tumbled 173.05% in 2026.
- Tracing CNTA's Times Interest Earned over 5 years: stood at -$18.88 in 2022, then gained by 27.52% to -$13.69 in 2023, then plunged by 119.79% to -$30.08 in 2024, then climbed by 18.95% to -$24.38 in 2025, then dropped by 19.79% to -$29.21 in 2026.
- Per Business Quant, the three latest CNTA Times Interest Earned figures stand at -$29.21 (Q1 2026), -$24.38 (Q4 2025), and -$18.61 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - | -29.21 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.21 |
| Dec 31, 2025 | -24.38 |
| Sep 30, 2025 | -18.61 |
| Jun 30, 2025 | -18.95 |
| Mar 31, 2025 | -10.70 |
| Dec 31, 2024 | -30.08 |
| Sep 30, 2024 | -18.15 |
| Jun 30, 2024 | -17.42 |
| Mar 31, 2024 | -14.27 |
| Dec 31, 2023 | -13.69 |
| Sep 30, 2023 | -15.82 |
| Jun 30, 2023 | -19.19 |
| Mar 31, 2023 | -20.84 |
| Dec 31, 2022 | -18.88 |
| Sep 30, 2022 | -25.51 |
| Jun 30, 2022 | -41.39 |
| Mar 31, 2022 | -35.48 |